Relevant bibliographies by topics / Targeted alpha therapy / Dissertations / Theses
To see the other types of publications on this topic, follow the link: Targeted alpha therapy.

Dissertations / Theses on the topic 'Targeted alpha therapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 15 dissertations / theses for your research on the topic 'Targeted alpha therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Song, Emma Yanjun Clinical School St George Hospital Faculty of Medicine UNSW. "Targeted alpha therapy for epithelial ovarian cancer." Awarded by:University of New South Wales. Clinical School - St George Hospital, 2007. http://handle.unsw.edu.au/1959.4/40874.

Full text
Abstract:
Purpose: Control of micrometastatic ovarian cancer in the peritoneal cavity remains a major objective in post-surgical treatment. The purpose of this project was to investigate the efficacy and toxicity of targeted alpha therapy (TAT) for ovarian cancer in vitro and in vivo in animal models and to select the optimal targeting vector for an ovarian cancer clinical trial. Animal models of ovarian, breast and prostate cancer were developed and for further TAT; a phase I melanoma clinical trial was supported, paving the way for an ovarian cancer clinical trial. Methods: The expression of the turn
APA, Harvard, Vancouver, ISO, and other styles
2

Andrews, Shannon. "FOLATE CONJUGATED DENDRIMERS FOR TARGETED ANTICANCER THERAPY." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/3497.

Full text
Abstract:
Anticancer therapeutics are often limited to suboptimal doses due to their lack of selectivity for tumor cells and resultant damage to healthy tissue. These limitations motivated researchers to develop tumor-specific delivery systems for improved therapeutic efficacy and reduced unintended cytotoxicity. Polyamidoamine dendrimers offer an ideal platform for designing targeted therapeutics with tunable characteristics that optimize pharmacokinetic behavior and targeting specificity. Ligand conjugation to dendrimer provides the biochemical interaction necessary to activate tumor-specific receptor
APA, Harvard, Vancouver, ISO, and other styles
3

Pashaeinejad, Masoumeh Physics Faculty of Science UNSW. "Targeted alpha-therapy:cell survival determination in melanoma tumours using Monte Carlo calculations." Awarded by:University of New South Wales. Physics, 2006. http://handle.unsw.edu.au/1959.4/23996.

Full text
Abstract:
This study investigates the Monte Carlo calculations of cell survival in metastatic subcutaneous melanoma cancer tumours. To achieve this goal, a Monte Carlo program called SLAB.FOR was developed by Prof. David Charlton. The program randomly places alphas from 213Bi in the medium, which is a cancer cell sized micro dosimeter with a SiO2 converter on the top and Si as the sensitive volume. Then the Monte Carlo program calculates the energy deposited by alphas and their chord length and also the dose deposited in the sensitive volume. To be able to use this program, some information was taken fr
APA, Harvard, Vancouver, ISO, and other styles
4

Toro-Gonzalez, Miguel. "LANTHANIDE-BASED CORE-SHELL NANOPARTICLES AS MULTIFUNCTIONAL PLATFORMS FOR TARGETED RADIONUCLIDE THERAPY AND MULTIMODAL MOLECULAR IMAGING." VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5647.

Full text
Abstract:
Lanthanide phosphate (LnPO4) and lanthanide vanadate (LnVO4) nanoparticles (NPs) are promising platforms for theranostic applications because of their chemical stability, low solubility, low toxicity, and unique luminescence and magnetic properties. Motivated by the high radiation resistance and ability to host actinides of naturally occurring lanthanide-based compounds, LnPO4 and LnVO4 NPs were studied as radionuclide carriers for targeted radionuclide therapy using in vivoα-generators, 223Ra, 225Ac, and 227Th. The implementation of these radionuclides has shown potential for the treatment of
APA, Harvard, Vancouver, ISO, and other styles
5

Petitprin, Aurélie. "Le RAFT-RGD radiomarqué avec un émetteur °- comme nouvel agent de radiothérapie interne vectorisée." Thesis, Grenoble, 2013. http://www.theses.fr/2013GRENS002/document.

Full text
Abstract:
Le RAFT-RGD radiomarqué avec un émetteur β- comme nouvel agent de radiothérapie interne vectorisée. L'intégrine αvβ3 est fortement impliquée en oncogenèse à travers son rôle dans la néoangiogenèse tumorale, dans la prolifération et la survie des cellules cancéreuses et dans le processus métastatique. L'intégrine αvβ3 est exprimée faiblement dans la plupart des tissus. Par contre, elle est fortement exprimée par les cellules endothéliales activées lors de l'angiogenèse et par les cellules de nombreux types de cancers invasifs. Ces caractéristiques font de l'intégrine αvβ3 une excellente cible p
APA, Harvard, Vancouver, ISO, and other styles
6

Doligalski, Michael Lawrence. "Design and Development of Peptidomimetic Ligands for Targeting Radiopharmaceuticals, Imaging Probes, and Immunotherapeutics in Oncologic Disease." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6492.

Full text
Abstract:
Cancer is a leading cause of morbidity and mortality in the developed world. While much has been learned about these diseases in the last few decades, one of the main barriers to widespread advancement is the heterogeneity of cancer biology. A growing body of evidence supports the idea that certain protein receptors are overexpressed on the surface of tumor cells as compared to normal tissues. These extracellular biomarkers provide a unique opportunity to selectively target the tumor with both imaging and therapeutic modalities. The research in this dissertation focuses on targeting proteins o
APA, Harvard, Vancouver, ISO, and other styles
7

Fouinneteau, Romain. "Design and evaluation of astatoaryl compounds stabilized against dehalogenation in oxidizing media." Electronic Thesis or Diss., Nantes Université, 2024. http://www.theses.fr/2024NANU1032.

Full text
Abstract:
La thérapie interne vectorisée alpha est une stratégie émergente pour le traitement des cancers. Le radiohalogène astate-211 (t1/2 = 7,2h) est l'un des émetteurs alpha les plus prometteurs. Malgré des applications cliniques initiales encourageantes avec le N- [211At]succinimidylastatobenzoate ([211At]SAB) comme groupe prosthétique pour marquer les anticorps, les études in vivo ont montré que la liaison carbone-astate est insuffisamment stable et conduit à la libération d'astate dans l'organisme, ce qui peut nuire à l'efficacité et à la sécurité du patient. Néanmoins, des études récentes ont mo
APA, Harvard, Vancouver, ISO, and other styles
8

Kostova, Vesela. "Shiga toxin targeted strategy for chemotherapy and cancer immunotherapy application using copper-free « Click » chemistry." Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCB144.

Full text
Abstract:
Pas de résumé<br>Recently targeted therapies appeared as attractive alternatives to classical antitumoral treatments. The approach, developed on the concept of targeting drug to cancer cells, aims to spear normal tissues and decrease the side effects. This doctoral dissertation focuses on developing new anticancer targeted treatments in the field of chemotherapy and cancer immunotherapy by exploiting an original targeting moiety, the B subunit of Shiga toxin (STxB). Its specific properties, such as, recognition with its receptor Gb3 overexpressed in cancer cells or in antigen-presenting cells,
APA, Harvard, Vancouver, ISO, and other styles
9

Kannengießer, Stefanie [Verfasser], and Thomas [Akademischer Betreuer] Fanghänel. "Optimization of the Synthesis of Ac-225-labelled DOTA-Radioimmunoconjugates for Targeted Alpha Therapy, based on Investigations on the Complexation of Trivalent Actinides by DOTA / Stefanie Kannengießer ; Betreuer: Thomas Fanghänel." Heidelberg : Universitätsbibliothek Heidelberg, 2013. http://d-nb.info/1177148838/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Larouze, Alexandre. "Dosimétrie de radioéléments émetteurs alpha pour la radiothérapie interne vectorisée." Electronic Thesis or Diss., Bordeaux, 2024. http://www.theses.fr/2024BORD0061.

Full text
Abstract:
La radiothérapie interne vectorisée (RIV) est une technique de traitement du cancer en médecine nucléaire qui consiste à coupler un radionucléide à une molécule vectrice capable de cibler spécifiquement les cellules cancéreuses. Les radionucléides utilisés cliniquement sont majoritairement des émetteurs β− (177Lu,131I, 90Y) ; néanmoins, un émetteur α (223Ra) a récemment été approuvé pour le traitement du cancer de la prostate. L’objectif de cette thèse est de caractériser - par l’intermédiaire d’un code Monte Carlo à structure de trace nommé TILDA-V - les dépôts d’énergie induits par les radio
APA, Harvard, Vancouver, ISO, and other styles
11

Gruntman, Alisha. "A Translational Pathway for Recombinant Adeno-Associated Virus Human Gene Therapy: From Target Identification and Animal Modeling of the Disease to Non-Human Primate and Human Studies." eScholarship@UMMS, 2011. http://escholarship.umassmed.edu/gsbs_diss/882.

Full text
Abstract:
Many steps go into developing a clinical viral gene therapy. The course starts with appropriate disease selection and moves through the many hurdles of in-vitro testing, animal model validation and proof-of-concept studies, all the way through pre-clinical large animal studies. In this thesis, I propose to outline the process of developing a translation pathway for a gene therapy using recombinant adeno-associated virus (rAAV). I will expand on this outline using data that I have generated during the course of my Ph.D. that ranges from animal model validation all the way through pre-clinical v
APA, Harvard, Vancouver, ISO, and other styles
12

Gruntman, Alisha. "A Translational Pathway for Recombinant Adeno-Associated Virus Human Gene Therapy: From Target Identification and Animal Modeling of the Disease to Non-Human Primate and Human Studies." eScholarship@UMMS, 2016. https://escholarship.umassmed.edu/gsbs_diss/882.

Full text
Abstract:
Many steps go into developing a clinical viral gene therapy. The course starts with appropriate disease selection and moves through the many hurdles of in-vitro testing, animal model validation and proof-of-concept studies, all the way through pre-clinical large animal studies. In this thesis, I propose to outline the process of developing a translation pathway for a gene therapy using recombinant adeno-associated virus (rAAV). I will expand on this outline using data that I have generated during the course of my Ph.D. that ranges from animal model validation all the way through pre-clinical v
APA, Harvard, Vancouver, ISO, and other styles
13

Crawford, Jason Raymond. "New technologies for At-211 targeted alpha-therapy research using Rn-211 and At-209." Thesis, 2016. http://hdl.handle.net/1828/7507.

Full text
Abstract:
The most promising applications for targeted alpha-therapy with astatine-211 (At-211) include treatments of disseminated microscopic disease, the major medical problem for cancer treatment. The primary advantages of targeted alpha-therapy with At-211 are that the alpha-particle radiation is densely ionizing, translating to high relative biological effectiveness (RBE), and short-range, minimizing damage to surrounding healthy tissues. In addition, theranostic imaging with I-123 surrogates has shown promise for developing new therapies with At-211 and translating them to the clinic. Currently,
APA, Harvard, Vancouver, ISO, and other styles
14

(11205204), Spencer D. Lindeman. "DESIGN, SYNTHESIS, AND PRECLINICAL EVALUATION OF LIGAND-TARGETED CONJUGATES FOR CANCER RADIOTHERANOSTICS." Thesis, 2021.

Find full text
Abstract:
For any drug candidate to be approved by the U.S. Food and Drug Administration, it must meet strict standards for safety and efficacy. While the field of nuclear medicine is over 100 years old, traditional methods such as external beams or systematic administration have rarely met these standards or have limited application. Ligand-targeted therapy and diagnostics, or “theranostics,” has emerged in the past several decades as an exciting field that offers new possibilities to design drugs that are both safe and effective. When applied to nuclear medicine, the field of ligand-targeted radioacti
APA, Harvard, Vancouver, ISO, and other styles
15

Richartz, Anja [Verfasser]. "Ein neues Target zur Therapie von Basaliom und spinozellulärem Karzinom : Inhibition der humanen DNA-Polymerase α [alpha] / vorgelegt von Anja Richartz". 2007. http://d-nb.info/988490277/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Targeted alpha therapy' for other source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography